WO2002041887A1 - Preparations seches de sirop - Google Patents
Preparations seches de sirop Download PDFInfo
- Publication number
- WO2002041887A1 WO2002041887A1 PCT/JP2001/010110 JP0110110W WO0241887A1 WO 2002041887 A1 WO2002041887 A1 WO 2002041887A1 JP 0110110 W JP0110110 W JP 0110110W WO 0241887 A1 WO0241887 A1 WO 0241887A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- dry syrup
- granules
- manufactured
- taken
- Prior art date
Links
- 239000006188 syrup Substances 0.000 title claims abstract description 25
- 235000020357 syrup Nutrition 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 12
- 239000008123 high-intensity sweetener Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 235000013615 non-nutritive sweetener Nutrition 0.000 claims description 7
- 206010013781 dry mouth Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 6
- 235000003599 food sweetener Nutrition 0.000 abstract description 3
- 239000003765 sweetening agent Substances 0.000 abstract description 3
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 229920002472 Starch Polymers 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 229910052708 sodium Inorganic materials 0.000 description 15
- 239000008107 starch Substances 0.000 description 15
- 235000019698 starch Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 8
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 8
- 239000004299 sodium benzoate Substances 0.000 description 8
- 235000010234 sodium benzoate Nutrition 0.000 description 8
- 108010011485 Aspartame Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000605 aspartame Substances 0.000 description 6
- 235000010357 aspartame Nutrition 0.000 description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 6
- 229960003438 aspartame Drugs 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000010724 Wisteria floribunda Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- 229940079839 sodium dehydroacetate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- -1 sucrose fatty acid ester Chemical class 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- YPJCOQNPDMQXAL-FKQPBZCOSA-L C(\C=C\C(=O)[O-])(=O)[O-].C(CCCCCCCCCCCCCCCCC)[Na].[Na+].[Na+] Chemical compound C(\C=C\C(=O)[O-])(=O)[O-].C(CCCCCCCCCCCCCCCCC)[Na].[Na+].[Na+] YPJCOQNPDMQXAL-FKQPBZCOSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- the present invention reduces the acidity of L-carbocistin, is convenient for prescription and carrying, and can be used as it is, or can be taken as it is suspended or dissolved in water. It is related to patch preparations. Background art
- L-carboxystin normalizes the content ratio of various mucins in the airway mucosa and reduces the viscosity of mucus. It also improves the mucus ciliary transport system by repairing mucosal epithelia such as ciliated cells, and promotes excretion of stored matter. Due to these effects, this drug has been found to be highly effective in expectoration of various respiratory diseases, drainage of chronic sinusitis, and drainage of exudative otitis media.
- Formulations of L-carbocistin include tablets, fine granules, suspension syrups, and syrups.
- liquid preparations such as syrup preparations require more time for dispensing work in pharmacies and hospitals than solid preparations, and are not convenient for patients to carry.
- solid preparations are difficult to take for children and elderly people with weak swallowing ability. It is hoped that this point will be improved, and that a formulation that is easier to take and that will be easier to formulate and carry around will be developed.
- L-carbocistin since L-carbocistin has a strong acidity, a large amount of sugar is added to L-carbocistin to reduce this acidity. Or special processing such as coating on granules containing L-carboxystin. As a result, preparations containing a large amount of saccharides increase the cost of production and packaging, increase the dose per dose, and are inconvenient for taking, dispensing, and carrying. In addition, coated pharmaceutical preparations have healthcare economic problems, such as complicated manufacturing processes and increased manufacturing costs. Disclosure of the invention
- the present inventors have proposed a simpler manufacturing process to reduce the acidity of L-carboxystin, without taking special processing such as coating into granules containing carbocystin, and taking and dispensing the preparation.
- the present invention comprises a sugar alcohol and a high-intensity sweetener, so that the acidity of L-carboxystin can be improved by a simple production process that does not require special processing such as coating.
- the purpose of the present invention is to provide a dry syrup formulation that has achieved a reduction in drug consumption.
- the dry syrup of L-carbocistine obtained in this way can be easily dispensed, convenient to carry, easy to take as it is, It can be taken even when suspended or dissolved in water, and can be taken by children and the elderly.
- the sugar alcohol used in the present invention is a polyhydric alcohol obtained by reducing a carboxy group of a sugar molecule.
- examples include mannitol, sorbitol, maltitol, powdered reduced maltose water, erythritol, xylitol, and the like. Two or more of these sugar alcohols may be used.
- the high-sweetness sweetener used in the present invention is a sweetener having a sweetness of 10 times or more that of sucrose.
- salts of glycyrrhizic acid such as aspartame, saccharin and its salts, glycyrrhizic acid and diglyceryl glycyrrhizinate, and acesulfa Mucarium, stevia, etc.
- glycyrrhizic acid such as aspartame, saccharin and its salts
- glycyrrhizic acid and diglyceryl glycyrrhizinate such aspartame, saccharin and its salts
- glycyrrhizic acid and diglyceryl glycyrrhizinate such aspartame, saccharin and its salts
- glycyrrhizic acid and diglyceryl glycyrrhizinate such aspartame, saccharin and its salts
- the production method in the present invention is not particularly limited, and any known method such as a fluidized bed granulation method, a stirring granulation method, a high speed stirring granulation method, a tumbling fluidized bed granulation method, and a dry granulation method. It can also be manufactured using
- a binder an excipient, a disintegrant, a flavoring agent, a lubricant, and a coloring agent are optionally used for the purpose of further enhancing the ingestibility and commercial value.
- a disintegrant e.g., a flavoring agent, a lubricant, and a coloring agent.
- a coloring agent e.g., a coloring agent for the purpose of further enhancing the ingestibility and commercial value.
- other pharmaceutical excipients e.g., a coloring agent for the purpose of further enhancing the ingestibility and commercial value.
- One or more of these additives may be used.
- binder that can be arbitrarily added as long as it can be used as a pharmaceutical additive.
- PVP polyvinyl alcohol
- HPMC hydroxypropyl methylcellulose
- arabian rubber powder polyvinyl alcohol
- Methylcellulose gelatin, pullulan and the like.
- Preferred binding agents include polyvinylpyrrolidone and hydroxypropylcellulose.
- the disintegrant has a function as a suspending agent that enhances the dispersibility of L-potassium when the dry syrup according to the present invention is prepared as a suspension.
- the disintegrant has a function as a suspending agent that enhances the dispersibility of L-potassium when the dry syrup according to the present invention is prepared as a suspension.
- microcrystalline cellulose, hydroxypropyl starch, carmellose, carmellose calcium, carmellose sodium, non-starch starch, corn starch, low substituted hydroxy Xyloxycellulose, clospopidone, croscarmellose sodium, canoleboximetyl starch sodium and the like can be mentioned. These may be two or more kinds.
- Preferred disintegrants include clospopidone, croscarmellose sodium, and carboxymethyl starch sodium.
- flavoring agent that can be arbitrarily added as long as it can be used as a pharmaceutical additive.
- Orangex Orange oil
- Orange essence spare mint oil Nozzle power oil
- Non-refractive oil Lemon oil
- Peach fleet grey / fle / fle / f, f / f, f / f, etc. can be mentioned.
- lubricant that can be arbitrarily added as long as it can be used as a pharmaceutical additive.
- examples thereof include hydrous silicon dioxide, corn starch, sucrose fatty acid ester, stearic acid and salts thereof, fumaric acid, sodium stearyl sodium fumarate, talc, polyethylene glycol and the like.
- coloring agent that can be arbitrarily added as long as it can be used as a pharmaceutical additive.
- iron sesquioxide yellow iron sesquioxide, caramel, and the like can be mentioned.
- the purpose of the present invention is to further enhance the solubility of L-carbocistine when preparing the dry syrup according to the present invention as a suspension or a dissolution solution.
- a pharmaceutical additive of a solubilizing agent can be optionally added.
- the solubilizing agent can be arbitrarily added as long as it can be used as a pharmaceutical additive.
- sodium citrate anhydrous, sodium citrate, sodium hydroxide, sodium hydrogen carbonate, sodium hydrogen carbonate, sodium hydrogen phosphate, anhydrous sodium include sodium phosphate and trisodium phosphate. These may be two or more kinds.
- preservatives that can be used as pharmaceutical additives such as sodium benzoate, sodium dehydroacetate, and potassium sorbate may be added. Wear.
- excipients such as partially alpha-modified starch can be blended.
- the obtained granules were dried with a through-air dryer (30 C type, manufactured by Fuji Padal Co., Ltd.), and sized with a sieve having openings of 500 ⁇ m to obtain granules.
- the granules contain hydrous silicon dioxide 1 5 g and 0.75 g of grapefruit were mixed and mixed to obtain a dry syrup.
- the obtained granules were dried with a Floco Ichiichi (FLO-15 type, manufactured by Freund Industries) and sized with a sieve with an opening of 500 ⁇ m to obtain granules. .
- FLO-15 type manufactured by Freund Industries
- a sieve with an opening of 500 ⁇ m To the granules, 105 g of partially alpha-starched starch, 5.25 g of orange oil and 78.75 g of aspartame were added and mixed to obtain a dry syrup.
- L-carbocistine 400 g to powdered reduced maltose water 650 g, cross carmellose sodium 600 g, carboxime stils tartanium 240 g, benzoic acid Take 48 g of sodium and fluidize it in Floco Ichiyo (FLO-15, manufactured by Freund Sangyo Co., Ltd.), and add a 3% aqueous solution of hydroxypropyl cellulose to 600%. 0 g was sprayed and granulated. The obtained granules After drying in a floco overnight (FLO-15 type, manufactured by Freund Sangyo Co., Ltd.), the granules were sieved with a sieve having an opening of 500 m to obtain granules. In this granule, 240 g of partially alpha-starched starch and 12 g of orange oil, Asno. Luteme (180 g) was vortexed and mixed to obtain a dry mouth liquid.
- FLO-15 Floco Ichiyo
- L-carbocistine 159,000 g in powdered reduced maltose aqueous solution 190,32 g, cross carmellose sodium sodium 340,0 g, ruboxime chill starch sodium 936 g , 187.2 g of sodium benzoate and 31.2 g of iron sesquioxide were mixed, and then 499.2 g of hydroxypropyl cellulose was added to 80% ethanol. Was added to the solution, and the mixture was stirred and granulated with a noise speed mixer (FS-GS100, Fukae Kogyo KK).
- the obtained granules are transferred to a floco overnight (MTT-20 OF type, manufactured by Freund Sangyo Co., Ltd.) and sieved with a sieve with openings of 500 ⁇ m to obtain granules.
- MTT-20 OF type manufactured by Freund Sangyo Co., Ltd.
- a sieve with openings of 500 ⁇ m to obtain granules.
- 1653.6 g of sodium anhydrous citrate, 468 g of powdered reduced maltose water solution, 936 g of partially alpha-starched starch, and Stroberie 3.12 g of licorice and 936 g of acenortam were added and mixed to obtain a dry mouth liquid.
- the obtained granules were dried in Flow Co. Yuichi (FBG-1 type, manufactured by Freund Sangyo Co., Ltd.) to obtain granules.
- FBG-1 type manufactured by Freund Sangyo Co., Ltd.
- To the granules are added 94 g of corn starch, 0.5 g of sto berry essence, 30 g of aspartame, and 10 g of diglycium glycyrrhinate. It was mixed to obtain a dry syrup.
- L-carbocistine 1 650 g in powdered reduced maltose syrup 190,32 g, croscarmone sodium 234,0 g, carboxyme 936 g of sodium chillstartina, 187.2 g of sodium benzoate and 31.2 g of iron sesquioxide were mixed, and then mixed with 499.2 g of hydroxypropyl cellulose.
- the solution dissolved in 0% ethanol was added in an amount of 7625 g, and the mixture was stirred with a high-speed mixer (FS-GS100, manufactured by Fukae Kogyo Co., Ltd.) and granulated.
- the obtained granules were dried with a flow coater (MTT-200F type, manufactured by Freund Sangyo Co., Ltd.) and sieved to obtain granules.
- MTT-200F type manufactured by Freund Sangyo Co., Ltd.
- To this granule 16.6 33.6 g of anhydrous sodium citrate, 4680 g of powdered reduced maltose aqueous solution, 936 g of partially alpha-starched starch, 46.8 g of peach flavor, Aspartame 936 was added and mixed to obtain a dry mouth agent.
- the present invention provides a dry syrup of L-carbocistin in which the acidity of L-carbocistin is reduced, so that it is easy to take as it is, and It can be taken even when suspended or dissolved in water, and can be taken by children and the elderly.
- the dry syrup of L-carbocistine of the present invention is a preparation which can be easily dispensed and which is convenient to carry.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002544066A JP4827367B2 (ja) | 2000-11-21 | 2001-11-20 | ドライシロップ剤 |
AU2002224053A AU2002224053A1 (en) | 2000-11-21 | 2001-11-20 | Dry syrup preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-353839 | 2000-11-21 | ||
JP2000353839 | 2000-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002041887A1 true WO2002041887A1 (fr) | 2002-05-30 |
Family
ID=18826533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010110 WO2002041887A1 (fr) | 2000-11-21 | 2001-11-20 | Preparations seches de sirop |
Country Status (3)
Country | Link |
---|---|
JP (4) | JP6154758B2 (ja) |
AU (1) | AU2002224053A1 (ja) |
WO (1) | WO2002041887A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010013357A (ja) * | 2008-07-01 | 2010-01-21 | Takada Seiyaku Kk | 高含量l−カルボシステインドライシロップ剤 |
JP2011213622A (ja) * | 2010-03-31 | 2011-10-27 | Kyorin Pharmaceutical Co Ltd | 医薬用ゼリー組成物 |
JP2012067136A (ja) * | 2000-11-21 | 2012-04-05 | Kyorin Pharmaceutical Co Ltd | ドライシロップ剤 |
WO2014096497A1 (es) * | 2012-12-19 | 2014-06-26 | Itf Research Pharma, S.L.U. | Formulaciones líquidas de carbocisteína de propiedades mejoradas |
JP2015199704A (ja) * | 2014-04-02 | 2015-11-12 | 大正製薬株式会社 | 経口用組成物 |
CN106232129A (zh) * | 2014-05-05 | 2016-12-14 | 勃林格殷格翰国际有限公司 | 快速溶解的颗粒 |
WO2018079734A1 (ja) * | 2016-10-28 | 2018-05-03 | 第一三共株式会社 | メマンチンまたはその薬学上許容される塩を含有する医薬組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5733930B2 (ja) * | 2009-09-09 | 2015-06-10 | 武田薬品工業株式会社 | 固形製剤 |
KR20120087723A (ko) * | 2011-01-28 | 2012-08-07 | 제이더블유중외제약 주식회사 | 건조 시럽 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017667A1 (en) * | 1992-03-12 | 1993-09-16 | Taisho Pharmaceutical Co., Ltd. | Composition for oral preparations |
JPH0827034A (ja) * | 1994-07-14 | 1996-01-30 | Nikken Chem Co Ltd | エリスリトール含有内用液剤 |
JPH08337532A (ja) * | 1995-06-14 | 1996-12-24 | Takeda Chem Ind Ltd | 医薬組成物 |
JP2000273051A (ja) * | 1999-03-19 | 2000-10-03 | Kobayashi Pharmaceut Co Ltd | 苦みがマスキングされた液状製剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0696536B2 (ja) * | 1988-02-26 | 1994-11-30 | 佐藤製薬株式会社 | 制酸剤含有内用懸濁液 |
EP0481294B2 (de) * | 1990-10-19 | 2001-04-11 | Spirig Ag Pharmazeutische Präparate | Feste, schnell-lösliche Arzneimittelzubereitung enthaltend N-Acetylcystein |
JPH0616556A (ja) * | 1992-07-02 | 1994-01-25 | Yoshitomi Pharmaceut Ind Ltd | 難溶性薬物含有製剤 |
JPH06157312A (ja) * | 1992-11-12 | 1994-06-03 | Shionogi & Co Ltd | 苦味改善テルフェナジンドライシロップ顆粒剤 |
JPH0717866A (ja) * | 1993-06-16 | 1995-01-20 | Meiji Seika Kaisha Ltd | 医薬組成物 |
DE69636864T2 (de) * | 1995-05-02 | 2007-05-31 | Taisho Pharmaceutical Co., Ltd. | Mittel zur oralen verabreichung |
AR004014A1 (es) * | 1995-10-13 | 1998-09-30 | Meiji Seika Kaisha | Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion |
JPH09227364A (ja) * | 1996-02-23 | 1997-09-02 | Grelan Pharmaceut Co Ltd | 安定なテプレノン製剤 |
WO1999053914A1 (fr) * | 1998-04-16 | 1999-10-28 | Ajinomoto Co., Inc. | Remedes contre la cirrhose biliaire primitive |
JP3596742B2 (ja) * | 1998-07-31 | 2004-12-02 | 日研化学株式会社 | 陽イオン交換樹脂製剤 |
JP2000191519A (ja) * | 1998-12-25 | 2000-07-11 | Nippon Kayaku Co Ltd | 薬効成分の不快な官能的性質が隠蔽された速放性粒状物 |
JP2000256192A (ja) * | 1999-03-05 | 2000-09-19 | Nissho Corp | カルボシステイン製剤 |
WO2002041887A1 (fr) * | 2000-11-21 | 2002-05-30 | Kyorin Pharmaceutical Co., Ltd. | Preparations seches de sirop |
-
2001
- 2001-11-20 WO PCT/JP2001/010110 patent/WO2002041887A1/ja active Application Filing
- 2001-11-20 JP JP2014017418A patent/JP6154758B2/ja not_active Expired - Lifetime
- 2001-11-20 JP JP2002544066A patent/JP4827367B2/ja not_active Expired - Lifetime
- 2001-11-20 AU AU2002224053A patent/AU2002224053A1/en not_active Abandoned
-
2008
- 2008-09-04 JP JP2008226643A patent/JP4987825B2/ja not_active Expired - Lifetime
-
2012
- 2012-01-05 JP JP2012000701A patent/JP5566408B2/ja not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017667A1 (en) * | 1992-03-12 | 1993-09-16 | Taisho Pharmaceutical Co., Ltd. | Composition for oral preparations |
JPH0827034A (ja) * | 1994-07-14 | 1996-01-30 | Nikken Chem Co Ltd | エリスリトール含有内用液剤 |
JPH08337532A (ja) * | 1995-06-14 | 1996-12-24 | Takeda Chem Ind Ltd | 医薬組成物 |
JP2000273051A (ja) * | 1999-03-19 | 2000-10-03 | Kobayashi Pharmaceut Co Ltd | 苦みがマスキングされた液状製剤 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012067136A (ja) * | 2000-11-21 | 2012-04-05 | Kyorin Pharmaceutical Co Ltd | ドライシロップ剤 |
JP2010013357A (ja) * | 2008-07-01 | 2010-01-21 | Takada Seiyaku Kk | 高含量l−カルボシステインドライシロップ剤 |
JP2011213622A (ja) * | 2010-03-31 | 2011-10-27 | Kyorin Pharmaceutical Co Ltd | 医薬用ゼリー組成物 |
WO2014096497A1 (es) * | 2012-12-19 | 2014-06-26 | Itf Research Pharma, S.L.U. | Formulaciones líquidas de carbocisteína de propiedades mejoradas |
JP2015199704A (ja) * | 2014-04-02 | 2015-11-12 | 大正製薬株式会社 | 経口用組成物 |
CN106232129A (zh) * | 2014-05-05 | 2016-12-14 | 勃林格殷格翰国际有限公司 | 快速溶解的颗粒 |
WO2018079734A1 (ja) * | 2016-10-28 | 2018-05-03 | 第一三共株式会社 | メマンチンまたはその薬学上許容される塩を含有する医薬組成物 |
JPWO2018079734A1 (ja) * | 2016-10-28 | 2019-06-24 | 第一三共株式会社 | メマンチンまたはその薬学上許容される塩を含有する医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5566408B2 (ja) | 2014-08-06 |
JP2012067136A (ja) | 2012-04-05 |
JPWO2002041887A1 (ja) | 2004-03-25 |
JP2014074079A (ja) | 2014-04-24 |
JP6154758B2 (ja) | 2017-06-28 |
AU2002224053A1 (en) | 2002-06-03 |
JP2009019054A (ja) | 2009-01-29 |
JP4827367B2 (ja) | 2011-11-30 |
JP4987825B2 (ja) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5566408B2 (ja) | ドライシロップ剤 | |
JP5255604B2 (ja) | ビグアナイド系薬物の内服製剤 | |
JP5859664B2 (ja) | 薬物の味がマスクされた経口用薬学組成物及びその製造方法 | |
TWI376243B (en) | Oral disintegrating tablet | |
US20070224268A1 (en) | Process for preparing oral calcium compositions | |
JP4965130B2 (ja) | 乾式直打速崩壊性錠剤 | |
WO1999018936A1 (fr) | Preparations solides rapidement solubles | |
IE61616B1 (en) | Pharmaceutical compositions | |
JPH01313420A (ja) | 医薬咀しゃく錠組成物 | |
JP2016174616A (ja) | 崩壊性組成物及び易崩壊性圧縮成型物 | |
WO2019208540A1 (ja) | 安定性に優れた固形製剤 | |
JP4814636B2 (ja) | ビグアナイド系薬物の内服製剤 | |
US20100048498A1 (en) | Stable non-dihydrate azithromycin oral suspensions | |
CN107149594A (zh) | 一种醋酸钙掩味颗粒及其制备方法 | |
JPWO2019208540A1 (ja) | 安定性に優れた固形製剤 | |
CN100998594B (zh) | 一种阿莫地喹固体口服药物组合物 | |
JPH07173065A (ja) | 速溶性の医療用アルギン酸ナトリウム造粒物およびその製造法 | |
WO2024023786A1 (en) | Orally disintegrating palatable formulations of drotaverine and method of preparation thereof | |
EP4081218A1 (en) | Orally dissolving formulations of prucalopride | |
JP2010013357A (ja) | 高含量l−カルボシステインドライシロップ剤 | |
CN116635013A (zh) | 口腔可分散的粉末组合物 | |
WO2019043427A1 (en) | FAST SELF-DISPERSION DOSAGE FORMS OF DEFERASIROX | |
TR201620498A2 (tr) | Aseti̇lsi̇stei̇n ve parasetamol i̇çeren farmasöti̇k bi̇leşi̇m | |
JP2002255793A (ja) | 粒状製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002544066 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |